CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation
Radovan Krejcir1, Lukasz Arcimowicz1, Lucia Martinkova1
1RECAMO, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Abstract:
CDK11 is a cyclin-dependent kinase with a role in transcription and RNA splicing and represents a potential target for cancer treatment. We show that blocking CDK11 activity with the OTS964 inhibitor causes p53 stabilisation through MDM2 downregulation. Under these conditions, p53 activates the expression of its downstream effector CDKN1A (p21WAF1), produced in two isoforms, the canonical p21C and the recently described p21L. We compared the ability of both isoforms to block proliferation and showed that p21L partially lost its inhibitory potential, likely due to the missing cyclin-binding Cy2 and PCNA-interacting motifs and its cytoplasmic localisation. We identified the epitopes of four p21WAF1 antibodies using phage display to determine isoform specificity. Moreover, we show that the trigger for p21L induction is inhibition of the spliceosomal protein SF3B1. CDK11 activates SF3B1 by phosphorylation, and inhibition of either SF3B1 or CDK11 induces p21L. We discovered an isoform similar to human p21L in murine cells, suggesting evolutionary conservation of CDKN1A alternative splicing. Our results uncover an unknown link between RNA splicing and proliferation control involving a novel isoform of a key cell cycle inhibitor.
Insights
Blocking cyclin-dependent kinase 11 (CDK11) stabilizes p53, leading to the production of a novel CDKN1A (p21WAF1) isoform, p21L. This isoform exhibits reduced proliferation control, revealing a new link between RNA splicing and cell cycle regulation.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Cycle Regulation
Background:
- Cyclin-dependent kinase 11 (CDK11) plays roles in transcription and RNA splicing.
- CDK11 is a potential therapeutic target in cancer treatment.
- CDKN1A (p21WAF1) is a key cell cycle inhibitor, with canonical (p21C) and novel (p21L) isoforms.
Purpose of the Study:
- To investigate the effects of CDK11 inhibition on p53 and CDKN1A isoforms.
- To compare the proliferation inhibitory potential of p21C and p21L.
- To elucidate the mechanism regulating p21L induction and its evolutionary conservation.
Main Methods:
- Inhibition of CDK11 using the OTS964 inhibitor.
- Analysis of p53 stabilization and MDM2 downregulation.
- Assessment of CDKN1A (p21WAF1) isoform expression and proliferation.
- Phage display to identify antibody epitopes for isoform specificity.
- Investigation of SF3B1 inhibition and its effect on p21L induction.
Main Results:
- CDK11 inhibition stabilizes p53 via MDM2 downregulation, inducing both p21C and p21L.
- The p21L isoform shows reduced proliferation inhibition due to altered motifs and cytoplasmic localization.
- p21L induction is triggered by inhibition of the spliceosomal protein SF3B1, which is phosphorylated by CDK11.
- An analogous p21L isoform was found in murine cells, indicating evolutionary conservation.
Conclusions:
- CDK11 inhibition impacts cell proliferation through differential regulation of p21WAF1 isoforms.
- The novel p21L isoform has diminished antiproliferative activity.
- A link exists between RNA splicing regulation (via SF3B1) and cell cycle control mediated by CDK11 and p21WAF1 alternative splicing.
Related Concept Videos
Inhibition of Cdk Activity
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Abnormal Proliferation
Positive Regulator Molecules


